Alan Nicholas

2.7k total citations · 1 hit paper
23 papers, 1.5k citations indexed

About

Alan Nicholas is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan Nicholas has authored 23 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 10 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan Nicholas's work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Genomics and Diagnostics (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Alan Nicholas is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Cancer Genomics and Diagnostics (10 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Alan Nicholas collaborates with scholars based in United States, Switzerland and Germany. Alan Nicholas's co-authors include Ann‐Lii Cheng, Richard S. Finn, Peter R. Galle, Philippe Merle, Andrew X. Zhu, Daneng Li, Lindong Li, Wendy Verret, В. В. Бредер and Michel Ducreux and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Alan Nicholas

23 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

2021 891 citations Ann‐Lii Cheng, Shukui Qin et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Nicholas United States	13	766	697	430	284	249	23	1.5k
Zhendong Chen China	13	331 0.4×	383 0.5×	208 0.5×	95 0.3×	141 0.6×	28	783
Yilin Li China	20	74 0.1×	633 0.9×	276 0.6×	107 0.4×	83 0.3×	57	1.2k
Hua Bai China	17	39 0.1×	858 1.2×	422 1.0×	82 0.3×	77 0.3×	43	1.3k
Ming‐Han Chen Taiwan	20	94 0.1×	199 0.3×	72 0.2×	215 0.8×	89 0.4×	66	1.1k
Hongping Yu China	18	80 0.1×	258 0.4×	114 0.3×	104 0.4×	52 0.2×	58	990
Marc Ballas United States	14	16 0.0×	554 0.8×	336 0.8×	120 0.4×	55 0.2×	46	905
Zihao Dai China	12	113 0.1×	164 0.2×	94 0.2×	46 0.2×	44 0.2×	23	857
Shivan Sivakumar United Kingdom	15	18 0.0×	643 0.9×	355 0.8×	35 0.1×	80 0.3×	40	1.0k
P. Mukhopadhyay United States	9	32 0.0×	463 0.7×	136 0.3×	85 0.3×	14 0.1×	27	658
Jeff Lin United States	15	28 0.0×	293 0.4×	125 0.3×	202 0.7×	21 0.1×	36	1.2k

Countries citing papers authored by Alan Nicholas

Since Specialization

Citations

This map shows the geographic impact of Alan Nicholas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Nicholas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Nicholas more than expected).

Fields of papers citing papers by Alan Nicholas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Nicholas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Nicholas. The network helps show where Alan Nicholas may publish in the future.

Co-authorship network of co-authors of Alan Nicholas

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Nicholas. A scholar is included among the top collaborators of Alan Nicholas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Nicholas. Alan Nicholas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Finn, Richard S., Peter R. Galle, Michel Ducreux, et al.. (2024). Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 13(6). 1–14. 12 indexed citations

Karam, José A., Robert G. Uzzo, Axel Bex, et al.. (2024). Adjuvant Atezolizumab in Patients with Sarcomatoid Renal Cell Carcinoma: A Prespecified Subgroup Analysis of IMmotion010. European Urology Oncology. 7(6). 1175–1178. 1 indexed citations

Lin, Nancy U., Priya Kumthekar, Solmaz Sahebjam, et al.. (2023). Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. npj Breast Cancer. 9(1). 94–94. 9 indexed citations

Grande, Enrique, Aristotelis Bamias, Matt D. Galsky, et al.. (2023). Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.. Journal of Clinical Oncology. 41(16_suppl). 4503–4503. 5 indexed citations

Li, Daneng, Han Chong Toh, Philippe Merle, et al.. (2022). Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer. 11(6). 558–571. 18 indexed citations

Lin, Nancy U., Mark D. Pegram, Solmaz Sahebjam, et al.. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of Clinical Oncology. 39(24). 2667–2675. 67 indexed citations

Đačić, Sanja, William D. Travis, Jennifer M. Giltnane, et al.. (2021). Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.. Journal of Clinical Oncology. 39(15_suppl). 106–106. 13 indexed citations

Cheng, Ann‐Lii, Shukui Qin, Masafumi Ikeda, et al.. (2021). Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. Journal of Hepatology. 76(4). 862–873. 891 indexed citations breakdown →

Finn, Richard S., Shukui Qin, Masafumi Ikeda, et al.. (2021). Abstract CT009: IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). Cancer Research. 81(13_Supplement). CT009–CT009. 12 indexed citations

10.

Ducreux, Michel, Andrew X. Zhu, Ann‐Lii Cheng, et al.. (2021). IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).. Journal of Clinical Oncology. 39(15_suppl). 4071–4071. 28 indexed citations

11.

Max, Xiaoju, Johanna C. Bendell, Herbert I. Hurwitz, et al.. (2020). Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 26(15). 4010–4017. 19 indexed citations

12.

Lin, Nancy U., Priya Kumthekar, Solmaz Sahebjam, et al.. (2020). Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study. Cancer Research. 80(4_Supplement). P1–18. 7 indexed citations

13.

Kwiatkowski, David J., Valerie W. Rusch, Jamie E. Chaft, et al.. (2019). Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).. Journal of Clinical Oncology. 37(15_suppl). 8503–8503. 106 indexed citations

14.

Yaung, Stephanie J., Alan Nicholas, Nicolas Sommer, et al.. (2018). Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 36(15_suppl). 3545–3545. 1 indexed citations

15.

Rusch, Valerie W., Jamie E. Chaft, Bruce E. Johnson, et al.. (2018). Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).. Journal of Clinical Oncology. 36(15_suppl). 8541–8541. 40 indexed citations

16.

Hurwitz, Herbert I., Benjamin Tan, James A. Reeves, et al.. (2018). Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). The Oncologist. 24(7). 921–932. 48 indexed citations

17.

Geary, David C., Alan Nicholas, Yaoran Li, & Jianguo Sun. (2017). Developmental change in the influence of domain-general abilities and domain-specific knowledge on mathematics achievement: An eight-year longitudinal study.. Journal of Educational Psychology. 109(5). 680–693. 129 indexed citations

18.

Hurwitz, Herbert I., Benjamin Tan, James A. Reeves, et al.. (2017). Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(4_suppl). 657–657. 5 indexed citations

19.

Lee, John J., John F. Palma, Lijing Yao, et al.. (2017). Correlation of pre- and post-induction plasma mutant allele fraction with progression-free survival (PFS) in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). e15118–e15118. 1 indexed citations

20.

Lin, Nancy U., Alisha Stein, Alan Nicholas, et al.. (2017). Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC).. Journal of Clinical Oncology. 35(15_suppl). 2074–2074. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact